These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1349 related articles for article (PubMed ID: 16273092)

  • 1. Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
    Bild AH; Yao G; Chang JT; Wang Q; Potti A; Chasse D; Joshi MB; Harpole D; Lancaster JM; Berchuck A; Olson JA; Marks JR; Dressman HK; West M; Nevins JR
    Nature; 2006 Jan; 439(7074):353-7. PubMed ID: 16273092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer biology: signatures guide drug choice.
    Downward J
    Nature; 2006 Jan; 439(7074):274-5. PubMed ID: 16421553
    [No Abstract]   [Full Text] [Related]  

  • 3. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    Glinsky GV
    J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
    Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
    Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
    Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
    JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
    Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
    PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing targeted therapy for human cancer by gene module maps.
    Wong DJ; Nuyten DS; Regev A; Lin M; Adler AS; Segal E; van de Vijver MJ; Chang HY
    Cancer Res; 2008 Jan; 68(2):369-78. PubMed ID: 18199530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age- and sex-specific genomic profiles in non-small cell lung cancer.
    Mostertz W; Stevenson M; Acharya C; Chan I; Walters K; Lamlertthon W; Barry W; Crawford J; Nevins J; Potti A
    JAMA; 2010 Feb; 303(6):535-43. PubMed ID: 20145230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anchorage-independent cell growth signature identifies tumors with metastatic potential.
    Mori S; Chang JT; Andrechek ER; Matsumura N; Baba T; Yao G; Kim JW; Gatza M; Murphy S; Nevins JR
    Oncogene; 2009 Aug; 28(31):2796-805. PubMed ID: 19483725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathway-based classification of lung cancer: a strategy to guide therapeutic selection.
    Nevins JR
    Proc Am Thorac Soc; 2011 May; 8(2):180-2. PubMed ID: 21543798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
    Jhan JR; Andrechek ER
    Oncogene; 2017 Jun; 36(25):3553-3561. PubMed ID: 28135251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.
    Rahman M; MacNeil SM; Jenkins DF; Shrestha G; Wyatt SR; McQuerry JA; Piccolo SR; Heiser LM; Gray JW; Johnson WE; Bild AH
    Genome Med; 2017 Apr; 9(1):40. PubMed ID: 28446242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
    Liu Y; Justilien V; Fields AP; Murray NR
    Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking oncogenic pathways with therapeutic opportunities.
    Bild AH; Potti A; Nevins JR
    Nat Rev Cancer; 2006 Sep; 6(9):735-41. PubMed ID: 16915294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
    Hu X; Stern HM; Ge L; O'Brien C; Haydu L; Honchell CD; Haverty PM; Peters BA; Wu TD; Amler LC; Chant J; Stokoe D; Lackner MR; Cavet G
    Mol Cancer Res; 2009 Apr; 7(4):511-22. PubMed ID: 19372580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
    Anders CK; Acharya CR; Hsu DS; Broadwater G; Garman K; Foekens JA; Zhang Y; Wang Y; Marcom K; Marks JR; Mukherjee S; Nevins JR; Blackwell KL; Potti A
    PLoS One; 2008 Jan; 3(1):e1373. PubMed ID: 18167534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer.
    Anguiano A; Potti A
    Expert Rev Mol Diagn; 2007 Nov; 7(6):837-44. PubMed ID: 18020912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.